
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
VJHemOnc Podcast
00:00
Response to Guilt or Anib in Relapsed Flip Three Mutated AML
Discussion on the response rate and duration of response to guilt or anib in individuals with relapsed flip three mutated acute myeloid leukemia, as well as the combination therapy and monitoring considerations.
Transcript
Play full episode